Explore More at wakehealth.edu


Clinical Trials News - 2 New Master Clinical Trial Agreements in Place

OSP recently completed its negotiations with two companies, Dermavant Services, Inc and Mitsubishi Tanabe Pharma to put a Master Clinical Trial Agreement in place with each of the companies.  Each one is a five year agreement and its purpose is to facilitate the contracting process related to Wake Forest’s participation in this company’s multi-center clinical trials.  There are several benefits to having these types of agreements in place.  First, it greatly reduces the contract negotiation time between Wake Forest and these companies as the legal/contractual terms of conduct of the study are already agreed upon, leaving basic study specifics to be worked out (i.e. study budget, timelines, etc).  Second, these types of agreements put Wake Forest in an advantageous position with these companies in terms of timing and paperwork – if they can provide us with the information quickly and without using their legal resources to negotiate a new CTA for every potential study, they are more apt to come to Wake Forest initially.  This has a rippling effect on overall timing and ultimately the success of our site in terms of site selection, site initiation, enrollment, revenue and, of course, patient care. 

Additional information on all of the Master CTAs that we have in place can be found on the CTSI website.

If you have questions regarding this agreement, any of the master agreements that you see on the website or have a suggestion for a company that you would like for OSP to work with to get a master agreement in place,  please contact Robyn Gore at 716-2846 or rgore@wakehealth.edu.

All Announcements

Connect with the CTSI

Stay up-to-date on research news from the Wake Forest Clinical and Translational Science Institute. Subscribe now!